Breaking News, Collaborations & Alliances

Passage Bio Officially Launches

With $115.5M Series A, to develop AAV-delivered therapeutics to treat rare monogenic CNS diseases

Passage Bio has officially launched with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures.    The funding will be used to develop a portfolio of five therapeutic candidates to treat rare monogenic CNS diseases. These programs are being developed under a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters